Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We set forth the results obtained after application of a hormonal protocol in prostate carcinoma (P.C.) on 257 patients controlled between June 1976 and June 1987, of whom we have selected 160 who fulfilled the following requirements: under 80 years old, confirmed anatomopathological diagnosis, state equal to or above the T1 of the Union International contre le Cancer (U.I.C.C.) classification, tolerance of treatment applied, clinical, analytical and complete, systematic iconographic follow up and minimum survival of more than one year. We treated those patients with localised P.C. (they have no demonstrable metastases), who in our series numbered 78 (78/160), with Diethylethylbestrol (D.E.S.) at an orally administered dose of 1 mgr. a day. In these the plasma testosterone dropped below 100 nanograms/l. in 57 cases (57/79). In this case metastases appeared in 22 cases (22/78). We treated those patients with metastatized P.C., who in our series numbered 59 (59/160), with orally administered Estramustine Phosphate (Estracyt) at a dose of 560 mgr. every 24 h. in two goes. In these the plasma testosterone dropped below 100 nanograms/l. in 50 cases (50/59). In this group the metastases disappeared in 7 patients, became stabilized in 30 and worsened in the other 22 patients. We carried out surgical orchiectomy on 49 patients (49/160): in 17 cases due to associate vascular pathology, in 13 cases for sociocultural reasons, in 5 cases because of advanced age and in 14 cases it was conducted on patients with a poor response to D.E.S.
 ...
PMID:[Hormonal treatment of cancer of the prostate]. 267 37

Hormone dependence of prostate cancer is well known. In 80% of cases with metastases, hormone suppression leads to the reduction of tumour volume and related disorders. However the treatment is generally palliative because malignant process recurs after about around 16 months. Mean survival is less than 3 years in these forms. Lack of response come always together with a poor prognosis, and there is 90% mortality at 2 years. Advanced prostatic cancer should not be treated with hormones if the patient has few symptoms and his quality of life is satisfactory. Symptomatic forms require hormone manipulation. Orchidectomy or LH-RH are recommended. Total androgen ablation (combined treatment) leads rapidly to more relief of symptoms, but its drawbacks and especially high cost indicate that its use should be weighed individually. Estramustine is not a first-lune treatment. Presently, there is no criteria to predict response to treatment.
 ...
PMID:[Medical treatment of prostate cancer]. 806 98

(1) The reference management of advanced-stage hormone-resistant prostate cancer is palliative treatment aimed at controlling pain and improving quality of life, namely analgesics and radiotherapy for painful bone metastases. (2) Mitoxantrone, a cytotoxic agent, has been granted marketing authorisation in this indication. Estramustine was already available in this setting. (3) The clinical assessment file on mitoxantrone mainly comprises two unblinded trials comparing a steroid + mitoxantrone combination with steroid alone. Mitoxantrone has not been compared with palliative care comprising radiotherapy. (4) One trial involved 161 patients with painful metastases. They were treated either with prednisone (10 mg/day by mouth) + mitoxantrone (12 mg/m2 intravenously every 3 weeks), or with prednisone alone. The other trial involved 242 patients with metastases that were not always symptomatic, who were treated either with hydrocortisone (40 mg/day orally) + mitoxantrone (14 mg/m2 intravenously every three weeks) or with hydrocortisone alone. (5) No trial showed a benefit of mitoxantrone in terms of the duration or quality of survival. The analgesic effect of mitoxantrone in the first trial was moderate, benefiting fewer than 20% of patients. The evidence shows that radiotherapy is effective in 80% of cases. (6) The main adverse effects of mitoxantrone are haematological and cardiovascular. The adverse effect profile of mitoxantrone does not appear to be any more favourable than that of radiotherapy. (7) In practice, for patients with advanced-stage hormone-resistant prostate cancer the reference palliative treatment for painful bone metastases remains analgesics plus radiotherapy. Mitoxantrone is of no use in this setting.
 ...
PMID:Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer. 1171 79

A 77-year-old man presented with complaints of dysuria, nocturia and painless nodule on his penis. Laboratory examination revealed elevated serum prostate-specific antigen (PSA) and CA19-9. Pathological examinations on prostate and penile biopsy specimens revealed prostate adenocarcinoma with penile metastasis. The patient was diagnosed as having prostate cancer stage D2 (T4N1M1) with bone, lymph node and penile metastases. There was no response to initial hormonal therapy with the surgical castration and diethylstilbestrol. However, decrease of the tumor size, as well as PSA and CA19-9 values were achieved after the combined chemotherapy with Estramustine, Paclitaxel and Carboplatin.
 ...
PMID:[Prostate cancer with penile metastasis: a case report]. 1636 13